Research programme: Gastrointestinal disorder therapeutics - Enterome Bioscience/ Takeda
Alternative Names: EB 120; EB 420Latest Information Update: 28 Jul 2023
At a glance
- Originator Enterome; Takeda
- Class Anti-inflammatories
- Mechanism of Action Gastrointestinal microbiome modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal disorders; Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in France
- 28 May 2020 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in France
- 28 May 2020 No recent reports of development identified for preclinical development in Ulcerative-colitis in France